- Silence to receive $60M upfront, $20M equity investment, $10M as an option fee/ selected target, ~$140M as development milestones, ~$250M as commercial milestones for each target along with royalties on sales of the therapies
- The multi-target alliance expected to initially work on 5 targets within the first 3yrs.
ofthe collaboration with AstraZeneca to get an option to extend the collaboration for further 5 siRNAtherapies targeting CV, renal, metabolic and respiratory diseases
- The companies will collaborate during the discovery phase while AstraZeneca will lead clinical development and commercialization of molecules, developed during the collaboration. Silence will get an option to co-develop two programs starting from P-II
Click here to read full press release/ article | Ref: Silence Therapeutics | Image: AstraZeneca